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Innate immune system is the first line of defence against invading pathogens that is critical for the overall survival of the host.
Human liver is characterised by a dual blood supply, with 80% of blood entering through the portal vein carrying nutrients and
bacterial endotoxin from the gastrointestinal tract. The liver is thus constantly exposed to antigenic loads. Therefore, pathogenic
microorganism must be eﬃciently eliminated whilst harmless antigens derived from the gastrointestinal tract need to be tolerized
in the liver. In order to achieve this, the liver innate immune system is equipped with multiple cellular components; monocytes,
macrophages, granulocytes, natural killer cells, and dendritic cells which coordinate to exert tolerogenic environment at the same
time detect, respond, and eliminate invading pathogens, infected or transformed self to mount immunity. This paper will discuss
the innate immune cells that take part in human liver inflammation, and their roles in both resolution of inflammation and tissue
repair.
1. Introduction
The immune system is made up of a coordinated network
of cells, tissues and organs, which are able to attack non-
self-exogenous pathogens and self-endogenous danger with
a complex set of defence mechanisms. It responds to
pathogens in two fundamental pathways: the primal strategy
of “identifying and destroying” (innate immunity) or the
specific detection and targeted killing process with regulation
and memory (adaptive immunity) [1].
The innate immune system is the first line of defence
against initial invading organisms and environmental
challenges during the initial critical hours and days of life
[2]. The overall survival of the host depends on its ability
to recognise and induce the appropriate defence signals for
the elimination of infectious microbes. Through anatomical
barriers (skin and mucosal epithelia of the gastrointestinal,
respiratory and reproductive tracts), soluble antimicrobial
factors (acute phase proteins, complement and cytokines),
and cellular components, the innate immune system
provides protective barriers between the inside of the body
and the outside world.
Innate immune cells [monocytes, macrophages, mast
cells, neutrophils and natural killer (NK) cells] are able to
recognise pathogen associated molecular patterns (PAMPs)
such as components of microorganisms [lipopolysaccharide
(LPS), glycolipids, flagellin, lipoproteins, viral RNA and
bacterial DNA] and endogenous ligands (such as heat shock
proteins released by damaged or necrotic host cells) via
their pattern-recognition receptors (PRRs), which include
receptors for bacterial carbohydrates and toll-like receptors
(TLRs). The TLRs and corresponding ligands, their impact
on innate immune system are described in Table 1. Engage-
ment of PAMPs with PRRs results in targeted and specific
destruction of the activating organism, infected or tumour
cells, by releasing cytotoxic agents or phagocytosis [3].
2. Liver as an Immunological Organ
Adult human liver is the largest internal organ in the
body, weighing 1.2–1.5 kg. It has a dual blood supply
with oxygenated blood entering through the hepatic artery
(20%) and blood rich in nutrients and bacterial endotoxin
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Table 1: Toll-like receptors and their ligands, target microbes, and eﬀector molecules are described.
TLRs Ligands Target microbes Eﬀector molecules
TLR1 Triacyl lipopeptides Mycobacteria Inflammatory cytokines
TLR2
Peptidoglycans,
Lipoprotein;
Zymosan
G+ bacteria
Mycobacteria
Yeast/other fungi
Inflammatory cytokines
TLR3 Viral double stranded RNA Viruses IFNβ
TLR4 LPS Gram-negative bacteria
IFNβ
Inflammatory cytokines
TLR5 Flagellin Bacteria Inflammatory cytokines
TLR6
Yeast zymosan
Diacyl lipopeptides
Mycobacteria
Yeasts and Fungi
Inflammatory cytokines
TLR7/8 Viral Single-stranded RNA Viruses IFNα
TLR9
Bacterial and viral CpG
DNA
Bacteria/virus
IFNα
Inflammatory cytokines
entering the liver through the portal vein (80%). The arterial
and portal-venous blood percolates through a network of
liver sinusoids generating a mixed arterial-venous perfusion
collected in the central vein and exit via three hepatic veins
and drain back into the inferior vena cava [4, 5]. The
liver is constantly exposed to antigenic loads of harmless
dietary and commensal products from the gastrointestinal
tract via portal vein and blood-borne antigens via hepatic
artery. Thus, it is prerequisite for the liver immune system
to be appropriately equipped in order to protect itself from
pathogens and metastatic cells, whilst tolerating harmless
self and foreign antigens. The liver innate cells (resident
macrophages, named, Kupﬀer cells, dendritic cells, NK and
NKT cells) and antimicrobial components (inflammatory
cytokines, chemokines, acute phase proteins, complement)
coordinate to achieve this critical task and eliminate invading
pathogens and infected or transformed self [5].
In this paper, we will describe the innate immune
cells phenotype, function in the context of human liver
inflammation.
3. Innate Immunity in Liver Inflammation
3.1. Acute Phase Proteins (APPs) and Complement System
3.1.1. Acute Inflammation and Acute-Phase Proteins. During
local liver injury or infection, resident Kupﬀer cells and
monocyte/macrophages initiate an immune response. Upon
phagocytosis of the pathogenic material, phagocytes release
a variety of chemical messengers such as tumour necrosis
factor alpha (TNFα), interleukin (IL)-1, and IL-6 that
initiate the acute-phase response and inflammation. Such
acute inflammation is characterised by the rise in concen-
tration of numerous plasma proteins, collectively termed
acute-phase proteins (APPs) [6]. APPs are a heterogeneous
group of plasma proteins, which are exclusively synthesised
in the liver and include pentraxins (C-reactive protein
(CRP), serum amyloid P (SAP), and the long pentraxin 3
(PTX)), serum amyloid A (SAA), serum mannose-binding
lectin, orosomucoid, inhibitors of proteases (α1-antitrypsin,
α1-antichymotrypsin, α1-ACH, α2-macroglobulin), coagu-
lation factors (fibrinogen, prothrombin, fVIII, plasmino-
gen), transport proteins (haptoglobin, hemopexin, ferritin),
and complement components [7]. The characteristic of these
APPs is that their concentration can be increased (positive
APPs) or decreased (negative APPs) by at least 50% in
inflammatory disorders [8, 9].
APPs are critical components of the innate immune
response restoring homeostasis after infection or inflam-
mation. The important tasks they serve include haemo-
static functions (e.g., fibrinogen), microbicidal and phago-
cytic functions (e.g., CRP and complement components),
antithrombotic (e.g., α1-acid glycoprotein), and antiprote-
olytic properties which are required for maintaining protease
activity at sites of inflammation (e.g., α2-macroglobulin, α1-
antitrypsin and α1-antichymotrypsin) [10].
One of the major acute-phase proteins in humans is C-
reactive protein. CRP belongs to the pentraxin superfamily
of acute phase reactants that has originally been named for
its ability to react with the C-polysaccharide of Streptococcus
pneumonia [8, 11]. CRP production increases rapidly up
to 1000-fold within 24–48 hours in response to infection,
trauma, and tissue infection, and its concentration reduces
the same rapidly after resolution of inflammation. Hence,
the measurement of CRP is widely used to monitor various
inflammatory conditions [8, 12]. CRP is produced mainly
by hepatocytes, but it can also be produced by Kupﬀer cells,
monocytes, and subsets of lymphocytes [11]. CRP binds to
phosphocholine and phospholipid constituents of foreign
pathogens and damaged cells and to chromatin in nuclear
DNA-histone complexes, thus acts as an opsonin for various
pathogens and activator of the complement system by
binding to Fc receptors. Interaction of CRP with Fc receptors
induces the production of proinflammatory cytokines that
further enhance the inflammatory response. One character-
istic of CRP is that it does not recognise specifically distinct
antigenic epitopes, but recognises altered self and foreign
molecules based on pattern recognition, thus provides early
defence through production of proinflammatory signals and
activation of the humoral and adaptive immune system
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[13]. In vivo studies in transgenic mice overexpressing CRP
have confirmed its anti-inflammatory eﬀects. Increased CRP
could prevent the adhesion of neutrophils to endothelial cells
by decreasing the surface expression of L-selectin, inhibiting
the generation of superoxide by neutrophils and stimulating
the synthesis of IL-1rα by mononuclear cells [8].
3.1.2. Complement System. The complement system is a
biochemical cascade of more than 35 proteins that plays
an important role in innate immune defence against var-
ious pathogens through cytolysis, chemotaxis (e.g., C5a),
opsonization (e.g., C3b), and activation of mast cells [14].
The complement system is activated through three diﬀerent
pathways: the classical, alternative, and mannose-binding
lectin pathway. Its activation is initiated by the binding of
one or more molecules of the above pathways on the surface
of the target cells. The classical pathway destroys antibody-
coated targets, apoptotic cells, Gram-negative bacteria, and
some viruses. The alternative pathway destroys a variety of
infectious agents including bacteria, viruses, and fungi in
addition to playing a role in the immune surveillance of
tumours, and the mannose-binding lectin pathway destroys
mannose-bearing pathogens [15, 16]. All three complement
activation pathways lead to the formation of C3 convertase,
which in turn leads to the formation of membrane attack
complex (MAC), a cytotoxic end-product of complement
system made up of C5b, C6, C7, C8, and polymeric C9,
that form a macromolecular pore capable of inserting itself
into cell membranes and lysing heterologous cells, including
bacteria and viruses, resulting in their death [16]. There
is growing evidence suggesting that complement proteins
not only serve as mediators of innate immune defence
against foreign pathogens but can also modulate diverse
developmental processes, such as cell survival, growth, and
diﬀerentiation in various tissues [17]. The anaphylatoxins
C3a and C5a, complement eﬀector molecules released after
complement activation, have been reported to be involved in
the priming phase of liver regeneration, contributing to both
the regulation of liver cell proliferation and hepatoprotection
[17–19]. In complement deficient mice, lack of complement
signalling results in impaired liver regeneration [19].
Depletion of serum complement before ischemia resulted
in a significant attenuation of the KC-induced oxidant
stress (enhanced oxidation of plasma glutathione) and also
prevented the accumulation of PMNs in the liver during the
reperfusion period suggesting that complement is involved in
the induction of a KC-induced oxidant stress, the priming of
KC and PMNs for enhanced reactive oxygen generation, and
the continuous accumulation of PMNs in the liver during
reperfusion [20]. Moreover, complement activation products
can augment adhesion of leukocytes to endothelium, since
C5b-9 and C5a can induce rapid translocation of P-selectin
from Weibel-Palade bodies to the endothelial surface. The
complement receptors CR3 and CR4 (CD18/CD11c) are
members of the β-integrin family, which promote interac-
tions between leukocytes and vascular endothelium [17].
3.2. Neutrophils. Neutrophils are polymorphonuclear cells
that belong to the granulocyte family of leukocytes. They are
themost abundant cells of the innate immune system and are
indispensable for their defence against invading infectious
pathogens. Neutrophils are generated in the bone marrow,
where they remain for further 4–6 days, thus spending
there the majority of their life [21, 22]. Their production is
extensive in steady state with 1-2× 1011 cells being generated
per day in normal human adult [23]. In systemic circulation
neutrophils form the majority of circulating leukocytes, but
they only consist <2% of total neutrophils. They have a very
short half-life (∼6–8 hours in humans and ∼11 hours in
mice) and are generally functionally quiescent [24]. During
episodes of infection, their number can be increased by up
to 10-fold. In steady-state conditions, circulating neutrophils
can home either to the spleen, liver, or return to the bone
marrow to be destroyed [25]. Alternatively, in the event of
a pathogenic invasion, neutrophils from peripheral blood
are rapidly recruited into peripheral tissues to fulfill their
primary role to eliminate microbial organisms.
3.2.1. Neutrophil Recruitment in Human Liver. A unique
feature of the liver is that it has several anatomical compart-
ments for leukocyte recruitment, including the endothelial
cells lining hepatic sinusoids, and the endothelial cells lining
the portal and terminal hepatic veins [4, 26]. Leukocytes are
able to adhere and migrate across such diﬀerent regions of
the hepatic microvasculature, but the majority of these cells
seem to enter the parenchyma via the hepatic sinusoids. The
endothelial cells lining the hepatic sinusoids have distinct
characteristics as they lack underlying basement membrane
and tight junctions but have fenestra [27]. They display
diﬀerences in adhesion molecule expression compared with
other endothelial cells of central and hepatic veins. Adhesion
molecules such as E- and P-selectin, which are expressed on
endothelial surfaces of hepatic arteries, portal and central
veins are absent in sinusoidal endothelial cells [28, 29].
Leukocyte recruitment (Figure 3) is a highly regulated
process dependent on sequential interactions with endothe-
lial adhesion molecules and chemokines. The initial interac-
tions between endothelium and leukocytes induce tethering
and rolling of the leukocyte on the endothelial surface via
transient bonds between selectins and their glycoprotein
ligands. This initial contact allows leukocytes to sample
the endothelial microenvironment for chemokines, which
can be secreted by the activated endothelium and immune
cells and are immobilized by glycosaminoglycans on the
endothelial cell surface. The binding of chemokines to
chemokine receptors on leukocytes leads to rapid G-protein
coupled signalling that triggers cytoskeletal rearrangement
and activation of leukocyte integrins. The activated integrins
are then able to bind to their ligands, members of the
immunoglobulin superfamily expressed on the endothe-
lial surface, hence firmly arresting the leukocyte on the
endothelium. In the final step, leukocytes pass through the
endothelial monolayer in a process named transendothelial
migration or diapedesis, following directional cues to the site
of infection or tissue injury [30, 31].
In the case of neutrophils, the initial step includes the
slowing of this leukocyte within the venule. The cell is loosely
tethered to the vessel wall and rolls along the endothelial
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surface at less than 50 μm/sec velocity. Neutrophil rolling
along the endothelium is mediated by the three members
of the selectin family (E-, P-, and L-selectin) and their
ligands. After rolling, neutrophils are firmly arrested on
the endothelium via CD18 integrin/intercellular adhesion
molecules (ICAMs) interactions. The adherent neutrophils
migrate through the endothelial junctions into the region
between the endothelium and its basement membrane. After
stopping briefly at this location, neutrophils migrate into
the surrounding tissue via β2-integrins (LFA-1, Mac-1)
and ICAM-1 [32, 33]. This neutrophil recruitment cascade
occurs in mesentery, brain, and skin in vivo and in vitro.
However, some of the adhesion mechanisms in sinusoids
may not be the same as in postcapillary venules.
However, the recruitment of neutrophils in the liver
displays a diﬀerent pattern [34]. Neutrophil recruitment and
accumulation in the hepatic sinusoids is independent of
selectins and β2-integrins, which are though required for
their recruitment to the postsinusoidal venules [35–37]. It
has been suggested that accumulation of neutrophils into
the sinusoids is mediated by mechanical trapping of these
cells in the narrow sinusoidal vessels due to changes of
the activated neutrophils themselves, sinusoidal endothelial
cell swelling, and additional low stress in these capillaries
[38]. McDonald et al. [39] have supported that CD44 and
its hyaluronan ligand (HA), which is extensively expressed
on the sinusoidal endothelial cells, are responsible for neu-
trophil recruitment in liver sinusoids, as proven by blocking
antibodies directed against either CD44 and HA. Recent
reports have also highlighted the CD44/HA interaction as the
dominant mechanism for neutrophil adhesion in sinusoids
during endotoxemia and ischemia reperfusion [39, 40].
Although the adhesion molecules are the important “tracks”
for neutrophil movement, their driving forces however
are the chemotactic factors that induce their migration
from systemic circulation to the site of infection. Such
factors are cytokines (TNFα, IL-1α, and IL-1β), activated
complement proteins, and CXC chemokine IL-8 (CXCL8,
specific neutrophil chemoattractant) [32, 41].
3.2.2. Neutrophil-Mediated Innate Immune Defence. Mature
neutrophils are professional phagocytic granulocytes with
numerous antimicrobial molecules (>300 proteins) stored
in their cytoplasmic granules. These granules are unspe-
cific molecules with high cytotoxicity and potential tissue-
damaging activity that can be also involved in many
neutrophilic processes including adhesion, migration, and
antibacterial activities [42]. Thus, neutrophils are considered
highly dangerous cells, whose action needs to be tightly con-
trolled [43, 44]. This characteristic explains why neutrophils
are mainly absent in tissues and body cavities in steady-state
conditions and are predominantly kept in reserve pools as
quiescent cells in the blood and bone marrow. This also
explains the reason that they are the first cells to be recruited
to the site of infection upon acute inflammation [45].
During an infectious insult in the liver, resident
macrophages and dendritic cells detect the presence of
invading pathogens (via PRRs/PAMPs mechanisms) and
will release chemokines CXCL8 (IL-8), CXCL1, 2, 3, CCL2,
3, 4 to attract neutrophils and monocytes at the site of
infection (Figure 1) [44, 46, 47]. Neutrophils are the first
phagocytes to arrive at the foci of microbial invasion, where
they change their phenotype, become activated, and release
cytotoxic antimicrobial molecules (reactive oxygen species
(ROS), oxidants, defensins, lactoferrin and cathelicidins)
[42, 48–51] as well as chemokines to attract primarily more
neutrophils as well as monocytes, which extend the lifespan
of the former from 6–12 hrs (at resting state) to 24–48 hrs at
the inflammatory sites [45] by factors such as IL-1β, TNFα,
G-CSF and GM-CSF [52].
In order for the infection to be eﬀectively controlled and
resolved, the neutrophils that are present at the infectious
foci need to undergo apoptosis, a mechanism that renders
them functionally quiescent [53]. Apoptotic neutrophil itself
represents an important anti-inflammatory stimulus to other
cells by producing “eat me” signals recognised by the
surrounding phagocytes to resolve the infection. Scannell
et al. [54] have identified the release of annexin 1 by
apoptotic cells as a soluble signal that promotes neutrophil
phagocytosis by macrophages. Moreover, the exposure of
phosphatidylserine (PS) residues on the apoptotic neutrophil
membrane allows recognition of PS with its receptors on
macrophages, which not only initiates phagocytosis but
also modifies the transcriptional profile of the macrophage,
increasing the production of IL-10 and TGFβ, two cytokines
associated with resolving the inflammatory response and
promoting tissue repair [43, 55].
3.2.3. Neutrophil-Mediated Liver Tissue Injury. Protective
immunity is always beneficial when it is well contained
and properly regulated. Excessive neutrophil accumulation
at the site of liver tissue injury may contribute to pathol-
ogy through relevant proinflammatory and tissue-damaging
eﬀects from these cytotoxic phagocytes [56]. Liver injury
mediated by neutrophils has been reported in a number of
experimental animal models such as Concanavalin (Con)A-
induced hepatitis [57, 58], ischemia-reperfusion injury [59,
60], alcoholic hepatitis [61, 62], endotoxemia [63], and
sepsis [64]. Although the neutrophils that are accumulated
in sinusoids are partially activated and primed, they cannot
cause liver injury. Prerequisite for their cytotoxicity is their
extravasation and adherence to parenchymal cells via ICAM-
1/Mac-1 interaction [38, 65]. Adherence to parenchymal cells
triggers the formation of reactive oxygen species and release
of proteases through degranulation [38]. Neutrophils gener-
ate superoxide through NADPH oxidase, and the resulting
hydrogen peroxide can either directly diﬀuse into hepato-
cytes or generate an intracellular oxidant stress. Neutrophil
myeloperoxidase also generates hypochlorous acid, a major
oxidant that also diﬀuses into target cells leading eventually
to hepatocyte death [66, 67]. The proteases cathepsin G
and elastase can also cause parenchymal cell necrosis, as
protease inhibitors have been shown to attenuate neutrophil-
induced liver injury [32, 68]. Neutrophils are detected in
acute liver injury such as alcoholic hepatitis. Recent study
from Lemmers and colleague suggested that IL-17 secreted
from Th17, a new lineage of T helper cells act on fibroblast
which in turn secreted IL-8 to attract neutrophils to site of
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Figure 1: Innate immune cells in liver inflammation. During an infectious insult in the liver (1) resident macrophages, Kupﬀer cells, are the
first immune cells to detect the presence of invading pathogens (bacteria, parasites, viruses, damaged, and/or necrotic cells) via PRRs/PAMPs.
(2) Upon activation Kupﬀer cells release cytokines TNFα, IL-1, and IL-6 as well as chemokines CXCL 1–3, CXCL-8, CCL-2–4 that initiate (3)
the acute-phase response and inflammation. Acute inflammation is characterized by the rise in plasma proteins, collectively named acute-
phase proteins (APPs) that include C-reactive protein (CRP) and complement components. (4) Proinflammatory cytokines released from
activated Kupﬀer cells can activate hepatic sinusoidal endothelial cells to upregulate adhesionmolecules (ICAM1 and 2, VCAM-1, MAdCAM
etc.) and in combination with the chemokines secreted from Kupﬀer cells can stimulate the recruitment of neutrophils and monocytes to the
liver. (5) Neutrophils are the initial phagocytes to arrive at the site of microbial invasion, where (6) they change their phenotype, they become
activated and release powerful and cytotoxic antimicrobial molecules such as reactive oxygen species (ROS), oxidants, defensins, as well as
chemokines to attract more neutrophils and monocytes. (7) Following their recruitment to the tissue, monocytes undergo diﬀerentiation
into (8) tissue macrophages (MDMϕ), which release TNFα, IL-1β, G-CSF, and GM-CSF factors that can extend the lifespan of neutrophils
thus sustaining their presence at the site of inflammation. (9) In order for inflammation to be resolved, the dangerous neutrophils at the
inflammatory loci undergo apoptosis and terminate the inflammatory process quickly. Apoptotic neutrophils represent an important anti-
inflammatory stimulus to other cells involved in the resolution of inflammation by producing “eat-me” signals recognised by the surrounding
phagocytes. Phosphatidylserine (PS) residues on the apoptotic neutrophil membrane allow recognition by its receptor on macrophages,
which not only initiates phagocytosis but also modifies the transcriptional profile of the Mϕ, increasing the production of IL-10 and TGF-b,
cytokines associated with resolution of inflammatory response and tissue repair. Basophils are short-lived cells that express MHC II and
CD80/CD86 costimulatory molecules, thus are able to present antigens to CD4+ T cells promoting their diﬀerentiation into Th2 cells via
release of IL-4 and IL-13. Eosinophils recruited to the liver release proinflammatory mediators including granule-stored cationic proteins,
cytokines, and chemokines. They also express MHC II, CD80/CD86, CD40, and ICAM-1; thus they are able to present antigens to T cells
initiating or amplifying antigenic-specific immune responses.
alcoholic hepatitis suggesting the link between adaptive and
innate immune system via cytokine IL-17 [69].
3.3. Monocytes, Macrophages and Kupﬀer Cells
3.3.1. Monocytes: Origin, Heterogeneity, and Function.
Monocytes originate from a common myeloid progenitor
cell in the bone marrow that is shared with neutrophils.
They are released in the bloodstream as nondiﬀerentiated
cells and circulate in the blood for 1–3 days [70]. Fol-
lowing recruitment to tissues, monocytes can diﬀerentiate
into tissue macrophages (Mϕs) or myeloid dendritic cells
(DCs) [71–75], replenishing the existing populations and
contributing to homeostasis maintenance, host defence,
tissue remodeling, and repair [70, 76, 77] (Figure 2).
Circulating monocytes constitute ∼5–10% of peripheral
blood leukocytes that show morphological heterogeneity
[78]. The heterogeneity among human monocytes has been
described since 1989 [79]. The diﬀerential expression of
CD14 (part of the receptor for LPS) and CD16 (also known
as FcγRIII) was initially traced in order to define two
major subsets in peripheral blood: the so-called “classical”
CD14++CD16 monocytes, typically representing up to 80%
of the monocytes in a healthy individual, and the “nonclassi-
cal” CD16+ monocytes comprising the remaining fraction
of monocytes (Figure 3) (paper in submission). It is now
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Figure 2: Monocyte and macrophage heterogeneity. Monocytes originate in the bone marrow where they develop from hematopoietic stem
cells (HSCs) via several diﬀerentiation steps and intermediate progenitor stages that pass through the common myeloid progenitor (CMP),
the granulocyte/macrophage progenitor (GMP), and themacrophage/DC progenitor (MDP) stages. TheMDP gives rise tomonocytes, which
are released in blood circulation where they remain for 1–3 days. In peripheral blood, circulating monocytes represent∼5–10% of peripheral
blood white blood cells (WBCs) and are a highly heterogenic population. Three main subtypes have been described based on the expression
of CD14 and CD16 receptors: the classical CD14++CD16, intermediate CD14++CD16+, and nonclassical CD14 low CD16++ monocytes.
In general, circulation monocytes are recruited to tissues where they can diﬀerentiate into dendritic cells or tissue macrophages (Kupﬀer
cells in the liver; microglial cells in the brain, etc.), replenishing the existing populations. Additional heterogeneity also exists between the
macrophages, with two major classes being identified: the classically activated (M1) and the alternatively activated (M2) macrophages. M1
macrophages are developed in response to TNFα and IFNγ as well as in response to microbial products such as LPS, and they produce in turn
proinflammatory cytokines including IL-1, IL-23, IL-6, and IL-12. M2 macrophages can develop in response to IL-4 and IL-13 cytokines and
play important roles in down-regulation of inflammation and tissue remodelling by releasing IL-10 and IL-1 receptor antagonist (IL-1Ra).
They also produce high levels of arginase, fibronectin, and a matrix-associated protein, βIG-H3.
apparent that further heterogeneity exists and is that the non-
classical subset can be further divided into the intermediate
CD14++CD16+ and the nonclassical CD14+CD16++ sub-
populations. These subsets diﬀer in many respects, including
adhesion molecule and chemokine receptor expression [80,
81]. For mouse blood monocytes, a subdivision into three
subsets similar to humans is also proposed that is classical,
intermediate, and nonclassical. Specifically, in mouse the
classical monocytes are Ly6Chi, CCR2hi, and CX3CR1low,
whereas the nonclassical monocytes are Ly6Clow, CCR2low,
and CX3CR1hi [81, 82].
Monocytes are members of the human mononuclear
phagocyte system, which is important for the host nonspe-
cific antimicrobial defence and tumour surveillance [82].
They are also a critical eﬀector component of the innate
immune system, equipped with chemokine receptors and
adhesion molecules to recruit to site of infection. Mono-
cytes secrete inflammatory cytokines, take up cells and
toxic molecules, thus contributing to the immune defence
against bacterial, protozoa, and fungal pathogens [83, 84].
Monocytes can kill bacteria by producing reactive nitrogen
intermediates (RNIs), reactive oxygen intermediates (ROIs),
and through the action of phagolysosomal enzymes [85].
3.3.2. Monocyte Recruitment to Human Liver. Monocyte
recruitment to the site of infection follows the general
paradigm of leukocyte traﬃcking cascades, which involves
rolling, adhesion, and transmigration. Monocytes are het-
erogeneous group and human monocyte subpopulations
are defined on the basis of the expression of cell-surface
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Figure 3: Innate immune cell (neutrophils, NK cells and monocytes) recruitment to hepatic inflammation. Human liver receives dual blood
supply from both portal vein and hepatic artery. During the inital event of hepatic inflammation, innate immune cells such as neutrophils,
monocytes and NK cells are recruited to the liver. Liver resident dendritic cells sample the foreign antigen and carry to local draining portal
lymph nodes where antigens are presented to the adaptive naive T cells. Following the antigen presentation, diﬀerent types of antigen-specific
T eﬀectors cells leave the nodes and drain back to systemic circulation. These T eﬀector cells recruit via hepatic sinusoid towards the site of
injury or inflammation. Th17 cells which secrete IL-17 attract neutrophils and also link innate and adaptive immunity.
markers. The classical CD14+ monocytes express high levels
of CCR2 (the receptor for CCL2/MCP-1), low levels of CCR5
and low levels of CX3CR1. Conversely, CD16+ monocytes
express high levels of CX3CR1 and CCR5 (receptors for
CCL3/MIP1α). Therefore, both CX3CL1 and CCL3 are
able to induce the transendothelial migration of CD16+
cells, whereas the recruitment of classical CD14+ cells
depends on CCL2 [76, 86]. Additional studies in human
peripheral blood monocyte subsets have shown that classical
CD14++CD16− monocytes express CCR1, CCR2, CCR4,
CCR5, CCR6, CXCR1, CXCR3, and CXCR5 chemokine
receptors, whereas the nonclassical CD16+ monocytes show
a limited chemokine receptor repertoire compared to CD14+
cells [87]. In mice, inflammatory monocytes express CD62L
(L-selectin), LFA-1 (αLβ2 integrin), Mac-1 (αMβ2 integrin),
PECAM-1 (CD31), and VLA-4 (α4β1). Therefore, initially,
monocytes undergo CD62L selectin-dependent rolling along
the vascular endothelium. Firm arrest is then mediated by
integrins; interaction of β2 integrins with ICAM-2 causes
firm arrest of monocytes in the absence of inflammation,
whereas interaction of β2 integrins with their countere-
ceptors ICAM-1 and ICAM-2 and of α4β1 with VCAM-1
mediates firm arrest and transmigration to inflamed tissues.
Monocyte transendothelial migration across endothelium
involves PECAM-1, CD99, CD226, and the junctional
adhesion molecules (JAMs), which are present at tight
junctions [88, 89]. After migration to the peripheral tissue,
monocytes uses α4β1- and α6β1 integrins to interact with
the extracellular matrix [82]. Previous study by Aspinall et al.
from our group has reported that the recruitment of CD16+
monocyte subset to the inflamed human liver is mediated by
VAP-1 and CX3CL1 [87].
3.3.3. Monocyte-Derived Macrophages and Kupﬀer Cells in
Human Liver. Inflammatory monocytes recruited at the site
of inflammation can diﬀerentiate into macrophages. Tissue
macrophages have a broad role in the maintenance of tissue
homeostasis, through the clearance of senescent cells and the
remodelling and repair of tissues after inflammation [90].
They are considered to be important immune eﬀector cells
that can clear approximately 2 × 1011 erythrocytes each day.
Macrophages are also involved in the removal of cellular
debris generated during tissue remodelling and rapidly and
eﬃciently can clear the cells that have undergone apopto-
sis. The receptors involved in these homeostatic processes
include scavenger receptors, phosphatidyl serine receptors,
the thrombospondin receptor, integrins and complement
receptors [91]. Moreover, necrosis that results from trauma
or stress generates cellular debris that need to be cleared
by macrophages. Phagocytosis of necrotic debris leads to
dramatic changes in their physiology, including alterations
in the expression of surface proteins and the production of
cytokines and proinflammatory mediators. Macrophages are
able to detect endogenous danger signals that are present in
the necrotic cell debris through TLRs, intracellular PRRs,
and IL-1R, most of which signal through the adaptor
molecule MyD88. This function makes macrophages one of
the primary sensors of danger in the host [91].
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Additional heterogeneity also exists between the
macrophages, with two major classes of macrophages
being identified: the classically activated macrophages
(M1) and the alternatively activated macrophages (M2)
(Figure 2). M1 Mϕs whose prototypical activating stimuli
are IFNγ and LPS (which induces TNF production)
generate proinflammatory cytokines, bactericidal mediators,
and promote strong IL-12-mediated Th1 responses. In
contrast M2 Mϕs whose stimuli are IL-4 or IL-13 play an
important role in the downregulation of inflammation
supporting Th2-associated eﬀector functions, tissue
remodelling, elimination of tissue debris, and apoptotic
bodies, as well as induction of angiogenesis [75, 92–94]. In
general, macrophages are equipped with a broad range of
pathogen-recognition receptors that make them eﬃcient at
phagocytosis and induce the production of inflammatory
cytokines [84].
Kupﬀer cells (KCs), named after the pathologist C. von
Kupﬀer are the liver resident macrophages which account
for 80–90% of total fixed tissue macrophages in the body
[95]. The origin of Kupﬀer cells has been speculated to
involve twomechanisms: replenishment by local self-renewal
and proliferation [96] and from circulating bone-marrow-
derived monocytes. Kupﬀer cells are present throughout the
liver residing within the lumen of liver sinusoids. Large
KCs are mainly located in the periportal region where they
are optimally located for response to systemic bacteria and
bacterial products that are transported from the gut to the
liver via the portal vein. Accordingly, periportal KCs have
higher lysosomal enzyme activities together with greater
phagocytic capacity than smaller KCs in midzonal and
perivenous regions. Furthermore, large KCs produce higher
levels of TNFα, PGE2, and IL-1 in contrast to the higher
levels of nitric oxide formation by small KC [97, 98].
Kupﬀer cells are active phagocytes, which uptake
intravascular debris, dead bacterial cells, and other blood-
borne particles, and are able to secrete various inflamma-
tory cytokines including IL-1, IL-6, TNFα, GM-CSF, and
chemokines such as MIP-1α (macrophage inflammatory
protein 1 alpha) and RANTES (regulated on activation, nor-
mal T-cell expressed and secreted). However, overproduction
of such inflammatory mediators by Kupﬀer cells can lead to
liver injury [99, 100]. Kupﬀer cells express several cell-surface
receptor complexes involved in immune stimulation. These
include complement receptors, Fc receptors, receptors for
lectin-containing opsonins such as plasma mannose-binding
lectin, adhesion receptors including those that bind ICAM-
1, TLRs, and receptors for polysaccharides of microbial and
host origin [101]. They also express high-aﬃnity Fcγ recep-
tors, which facilitate phagocytosis of IgG-coated particles, as
well as receptors for IgA, galactose, and mannose receptors,
and scavenger receptors which are capable of directly binding
microbial surface components [101].
3.3.4. Monocyte/Macrophage-Mediated Innate Immune
Defence. Resident macrophages and dendritic cells are
the first to detect the presence of invading pathogens by
using invariant PRRs that recognise conserved PAMPs on
extracellular and/or intracellular microbial components.
Initially damaged cells spill cytoplasmic and nuclear
components into the extracellular milieu, and these “alarm
signals” activate tissue resident macrophages. CLEC4E is a
transmembrane C type lectin, which has been reported to
be involved in initiating the early inflammatory response
after necrotic cell death [102]. The subsequent production
of proinflammatory cytokines and chemokines including
TNF, IL-6, CXCL1, CXCL2, CXCL3, CXCL8, CCL2, CCL3,
and CCL4 can stimulate the recruitment of neutrophils
and monocytes [103]. Granule proteins discharged from
activated neutrophils anchor on endothelial proteoglycans
and are recognised by monocytes that roll along the
endothelium, thus promote their firm adhesion. Moreover,
azurocidin, LL-37, and cathepsin G, proteases released from
activated recruited neutrophils, activate formyl peptide
receptors on classical inflammatory monocytes and promote
their extravasation. Neutrophil granule proteins can promote
de novo synthesis of monocyte-attracting chemokines by
neighbouring endothelial cells and macrophages. In
resolution of inflammation, apoptosis of neutrophils holds
a central position as it brings to an end the sustained
recruitment of neutrophils, while the phagocytic clearance
of apoptotic neutrophils reprogrammes macrophages to an
anti-inflammatory phenotype [104].
3.3.5. Monocyte/Macrophage-Mediated Liver Tissue Injury.
Monocytes/macrophages have an essential role in antimi-
crobial immune defence and are able to promote tissue
healing and repair. However, they can also contribute to
tissue destruction during some infections and inflammatory
diseases [82]. The cytotoxicity of infiltrating macrophages
or Kupﬀer cells has been reported in ischemia-reperfusion
injury [105], endotoxemia [106], galactosamine hepatotoxi-
city [107], and corynebacterium parvum/endotoxin-induced
liver injury [108]. It has been suggested that infiltrating
macrophages and Kupﬀer cells mediate their cytotoxic eﬀects
through the production of reactive free radicals and specifi-
cally reactive oxygen species and proinflammatory cytokines
including TNFα, IL-1β and IL-6. In addition, activated
Kupﬀer cells can induce the infiltration of neutrophils. Again,
proinflammatory cytokines released by Kupﬀer cells are
thought to be important in the development of neutrophil-
mediated tissue injury [59]. Previous study of Duﬃeld et al.
[109] demonstrated that deletion of macrophages either dur-
ing injury or during repair and resolution has dramatically
diﬀerent eﬀects on the overall fibrotic response. Specifically,
in progressive inflammatory injury, macrophage depletion
results in amelioration of fibrosis, whereas depletion during
recovery results in a failure of resolution with persistence
of cellular and matrix components of the fibrotic response.
Hepatic macrophages have been implicated in APAP-induced
liver hepatotoxicity (acetaminophen overdose), through the
production of proinflammatory cytokines and mediators
such as TNFα, IL-1β, and NO [110]. On the other hand,
however, there are studies which described protective role of
kupﬀer cells in acetaminophen-induced hepatic injury [111,
112]. The current concept suggests the role of macrophages
predominantly in tissue repairs especially the newly recruited
tissue macrophages [113].
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3.4. Mast Cells
3.4.1. Origin and Phenotype. The mast cell is originally
derived from the pluripotent haemopoetic stem cell. An
immature version of the mast cell, an undiﬀerentiated
CD34+ and CD117+ progenitor cell, is released from the
bone marrow into the blood stream [114, 115]. Mast cells
are sessile and predominantly inhabit perivascular dermal
and submucosal (respiratory/gastrointestinal/genitourinary
tracts) connective tissue and lymph nodes [116]. They
mature only once they have reached their tissue destination.
The stem cell factor, c-kit, plays a critical role in the
maturation process of the mast cell. Mast cells can be broadly
divided into two categories, connective tissue mast cells,
which are known as mast cell tryptase and chymase (MCTC)
that release IL-4, and mucosal mast cells also known as mast
cell tryptase (MCT) and produce IL-5 and IL-6 [117]. Once
resident in the tissue, the mast cell has a life span of several
months. They can proliferate, have a plasticity potential
[115], and are mainly involved in Th2 immune response at
the infected sites.
3.4.2. Mast Cells in Innate Immune Response. Mast cells
are among the first responders during infection that also
provide immediate action by recruiting other immune
cells to the scene of inflammation. Mast cells are large
cells whose content is dominated by cytoplasmic granules.
These cytoplasmic granules contain a variety of mediators
including serotonin, histamine, cytokines, chemokines, and
leukotriene. Histamine on its own composes 10% of the
entire weight of themast cell which illustrates the importance
of the cytoplasmic granules to the function of the mast cell.
Degranulation of mast cells and release of the mediators
occur primarily via an IgE-mediated pathway but also
via surface receptor binding sites including TLRs and β2
integrin.Mast cells have receptors, known as FcεRI, with high
aﬃnity for IgE on their surface. In fact the receptors have
such high aﬃnity for IgE that there is very little circulating
IgE, asmost is bound tomast cells already. The binding of IgE
to FcεRI creates a sensitised mast cell ready to degranulate.
The degranulation occurs when bi- or multi-valent antigen
binds to the IgE causing cross-linking between the IgE.
This leads to rapid exocytosis of the stored mediators,
degranulation. This can also occur when substances such
as neuropeptides and anaphylatoxins C3a and C5a bind to
receptors on the mast cell surface. Toll-like receptor ligands
can bind to toll-like receptors on the surface of mast cells
and cause secretion, rather than degranulation of cytokines,
chemokines, and lipid mediators [118].
Mast cells can amplify or suppress diﬀerent areas of both
innate and adaptive immunity depending on the concentra-
tion and type of the mediator released. The main mediators
contained in the mast cell are histamine, heparin, cytokines,
chemokines, and lipid mediators. Histamine and heparin are
able to increase vascular permeability, cause smooth muscle
contraction, and directly kill parasites. The major role of
mast cells in innate immunity is to recruit neutrophils which
can either enhance immune defence of host or can lead to
immunopathology [118]. Lipid mediators are also involved
in smooth muscle contraction, and can increase vascular
permeability as well as neutrophil, eosinophil and platelet
activation and mucus secretion.
3.4.3. Mast-Cell-Mediated Liver Tissue Injury. The number
of mast cells within the liver is proportionately low in
comparison to other tissues. The density of mast cells is
calculated at between 1.2 and 3.9 cells per square millimetre
of human liver. Hepatic mast cells are mostly situated within
connective tissue adjacent to the hepatic artery, hepatic vein
and bile ducts of the portal tract [119]. Recent studies
have shown the role of intrahepatic mast cells in diﬀerent
chronic liver diseases [119]. Increased mast cell numbers
have also been reported in liver fibrosis and hepatitis [120]
and have been involved in acute hepatitis [121], primary
biliary cirrhosis [122, 123], primary sclerosing cholangitis
[123], hepatocellular carcinoma and cholangiocarcinoma
[124, 125].
3.5. Basophils. Basophils are granulocytes that develop from
hematopoietic stem cells in the bone marrow. They leave
bone marrow after maturation, enter systemic circulation,
and finally migrate to the inflammatory sites, where they play
essential eﬀector functions in response to parasite infection
and allergic inflammation [126, 127].
3.5.1. Origin and Phenotype. Basophils are short-lived cells
(lifespan of 2-3 days) that account for less than 1% of
circulating granulocytes in the blood [128]. However, their
low baseline numbers can be expanded in response to
growth factors such as IL-3, which has been reported to
be important for basophil activation, population expansion,
and survival [129]. Basophils express the high-aﬃnity IgE
receptor (FcεR1) present in a tetramer form (αβγ2) [130],
and their activation can be induced in IgE-dependent
(by IgE/FecεR1 interaction) and IgE-independent manner
(by cytokines (IL-3, IL-6, IL-18, IL-33, TNFα, and GM-
CSF), antibodies (IgG and IgD), allergens, parasite antigens,
toll-like receptor (TLR) ligands and complement factors).
Activation of basophils results in their degranulation and
release of pro-formed (histamines) and newly synthesized
lipid mediators, cytokines (IL-4, IL-13, IL-6, TNFα, and
thymic stromal lymphopoietin (TSLP)) and chemokines,
which are essential players in vascular reaction, exudation,
leukocyte accumulation and wound healing [131, 132].
Basophils are mainly found in the blood and spleen
and upon exposure to stimuli such as allergens or parasites
they become activated. Activated basophils are then able
to migrate to lymph nodes [133–135]. Basophils express
a wide spectrum of chemoattractant receptors, such as
cytokine receptors (e.g., IL-3R, IL-5R, GM-CSFR) [130,
136], chemokine receptors (CCR1, CCR2, CCR3, CXCR1,
CXCR3 and CXCR4) [137–141], and receptors for more
pleiotropic chemotactic factors such as receptors for com-
plement components C3a and C5a, formyl-methionine-
leucine-phebylalaning (fMLP), platelet-activating factor
(PAF), leukotriene B4 (LTB4) [142–144]. Thus, basophils
have the potential to respond to a wide variety of inflam-
matory stimuli, and some basophil populations migrate to
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draining lymph nodes, while others accumulate in inflamed
tissues during an ongoing inflammatory response.
3.5.2. Basophil Recruitment and Function in Lymph Nodes
and Tissues. Basophil recruitment from the peripheral
circulation to the sites of infection occurs through the
multistep process of leukocyte recruitment that has been
described above. In vitro studies have shown that TNFα
and IL-1 enhance basophil adhesion on endothelial cells,
possibly through induction of basophil adhesion molecule
expression.Moreover, it has been reported that IL-3 increases
basophil adhesiveness to endothelial cells, possibly by
increasing CD11b, an integrin that interacts with ICAM-1,
fibrinogen and C3bi. CD11b and CD11c are also induced on
the surface of basophils after activation [145].
Although for many years it has been well accepted
that basophils are late-phase eﬀector cells that migrate to
the site of inflammation after the establishment of a Th2
cytokine response, recent studies have provided evidence
that basophils can also play a central role in the induction
and propagation of a Th2 cytokine-mediated immunity and
inflammation [146, 147]. In the lymph nodes, basophils
are able to directly interact with naive CD4+ T cells and
induce their diﬀerentiation into Th2 cells. They express
MHC class II and costimulatory molecules CD80 and CD86,
thus basophils can present antigen via MHC class II and can
provide IL-4 that promotes the diﬀerentiation of naı¨ve T cells
[147]. Basophils can also produce IL-13 upon stimulation
with Ag/IgE complexes and can strongly release IL-4 and IL-
13 in response to IL-3 and IL-18 or IL-33, further supporting
their role in the development of Th2 cells [147]. Interestingly,
independent groups have demonstrated that basophils are
the predominant antigen-presenting cell (APC) in inducing
Th2 responses against helminth parasites and allergens [133,
146, 148].
3.5.3. Basophils in Liver Inflammation. Studies reporting the
role of basophils in human liver inflammation are very
limited. It has been described that infection with intestinal
nematode Nippostrongylus brasiliensis induces robust Th2
immune responses and also enhances basophil generation
in the bone marrow and subsequent accumulation in the
peripheral tissues, including liver, lung, and spleen [149].
Further studies have also shown that basophils isolated from
the spleen, liver or bone marrow are able to initiate Th2 cell
development in the presence of antigens and DCs [150, 151].
3.6. Eosinophils
3.6.1. Origin, Phenotype, and Function. Eosinophils develop
and mature in the bone marrow from multipotent
hematopoietic progenitor cells of a myeloid lineage in IL-
3, IL-5 and GM-CSF dependent manner. IL-5 has been
described as the major lineage diﬀerentiation factor as well
as the stimulus for eosinophils to leave the bone marrow
and enter the circulation [152]. In the blood, mature
eosinophils circulate for a short time (half-life of 8–18
hours), and then migrate out of the vessels into tissue. They
consist approximately 1–3% of total circulating white blood
cells, since a large pool remains in the bone marrow and
the vast majority is located in the tissues, particularly at
the mucosal surfaces of the gastrointestinal tract (lamina
propria), mammary gland, respiratory and reproductive
tracts [153–155].
3.6.2. Eosinophil Recruitment to Tissue. Eosinophils
express an array of cell surface molecules including
immunoglobulin receptors for IgG (FcγRII/CD32) and IgA
(FCαRI/CD89), complement receptors (CR1, CR3, and
CD88), leukotriene receptors (CysLT1R and CysLT2R, LTB4
receptor), prostaglandin receptors (PGD2 type 2 receptor),
platelet activating factor receptor (PAF), and toll-like
receptors (particularly TLR7/8), cytokine receptors (IL-3R,
IL-5R, GM-CSF that promote eosinophil development, as
well as receptors for IL-1α, IL-2, IL-4, IFNα, and TNFα),
chemokine receptors (CCR1 and CCR3) and adhesion
molecules (VLA/α4β1, α4β7, Siglec-8) [130].
The migration of eosinophils from the blood into tissues
involves selective adhesion pathways and chemoattractants.
Chemoattractants for eosinophils include platelet-activating
factor (PAF), complement component C5a [156], IL-16
[157], RANTES [158], MCP-3 [138] and eotaxin [159,
160]. Eosinophils can pass through post-capillary venules
into tissues following chemoattractants in several steps
of recruitment cascades of rolling, firm adhesion, and
transendothelial migration. At the initial steps of tether-
ing and rolling on endothelium, eosinophils make use of
the receptors L-selectin, PSGL-1 and VLA-4 (α4β1), that
interact with their counter receptors GlyCAM-1, CD34
and MAdCAM-1 (all L-selectin ligands), P-selectin and
VCAM-1, respectively on the surface of endothelial cells
[161, 162]. Following rolling, eosinophil integrins LFA-1
(CD11a/CD18), Mac-1 (CD11b/CD18), VLA-4 and α4β7
become activated and lead eosinophils to firmly arrest on
ICAM-1, ICAM-2, VCAM-1 and MAdCAM-1, respectively
on the endothelial surface [163]. In order to infiltrate
into the tissue, eosinophils need to penetrate gaps between
the endothelial cells. Utilizing Mac-1/ICAM-1 interactions
and PECAM-1/PECAM-1 homotypical interactions between
both cells at transendothelial junctions, eosinophils are able
to translocate to the underlying basement membrane and
through the extracellular matrix into the tissue [164, 165].
3.6.3. Eosinophils in Innate Immune Defence. Activated
human eosinophils are able to defend host against parasites,
fungi and invading bacteria, by using functionally important
receptors such as TLRs (TLR1, TLR4, TLR7, TLR9, and
TLR10), responsible for recognition of conserved motifs
in those pathogens [166]. Proteolytic enzymes released by
various microbes and allergens, cross-linking of IgG or IgA
Fc receptors, IL-3, IL-5, GM-CSF, CC chemokines and PAF
mediators can potentially induce activation of eosinophils
[130].
Eosinophils are characterised by their cytoplasmic gran-
ules that contain cationic proteins: major basic protein
(MBP), eosinophil-derived neurotoxin (EDN), eosinophil
cationic protein (ECP), and eosinophil peroxidase (EPO).
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These basic proteins play key roles in killing parasites,
microorganisms, and tumour cells [156]. Degranulation of
eosinophils can be induced by soluble stimuli, such as IL-
5, GM-CSF, eosinophil-chemotactic cytokines CCL5 and
CCL3, the lipid mediator PAF, the complement fragments
C5a and C3a. The granule proteins, MBP and EPO acting
in an autocrine manner, and the integrin Mac-1 which plays
a role in eosinophil recruitment can also play a role in
eosinophil degranulation [158, 167, 168].
At the sites of inflammation, recruited eosinophils
release proinflammatory mediators including granule-stored
cationic proteins, and newly synthesized eicosanoids,
cytokines and chemokines including TGFα, TGFβ, IL 3–
5, IL-8, IL-10, IL-12, IL-13, IL-16, IL-18, TNFα, CCL-5
and CCL11 and profibrotic and angiogenic factors such
as osteopontin, VEGF and MMPs [169–172]. They also
promote Th2 responses. Eosinophils also possess the ability
to internalise, process and present antigenic peptides within
the context of surface-expressed major MHC class II. They
express CD80, CD86, CD40 and ICAM-1 thus they are
capable to provide costimulatory signals to T cells, present
antigens to naı¨ve and memory T cells and initiate/amplify
antigen-specific immune responses. In healthy individuals,
circulating eosinophils are devoid of MHC class II, but they
are induced to express MHC II and costimulatory molecules
upon exposure to appropriate cytokine stimuli and transmi-
gration through endothelial cell monolayer [173–175].
IL-5, IL-3 and GM-CSF besides being growth and
maturation factors for eosinophils, can also enhance several
eosinophil functions. Th2 cytokines, IL-4 and IL-13 can also
activate eosinophils.
3.6.4. Eosinophils in Liver Injury. Activated eosinophils have
been suggested to play important roles in the pathogenesis
of various liver diseases including primary biliary cirrho-
sis (PBC) [122, 176, 177]; primary sclerosing cholangitis
(PSC) [178, 179] idiopathic hypereosinophilic syndrome
[180, 181], drug-induced liver injury [182, 183], graft-
versus-host disease [184], and hepatic allograft rejection
[185–189]. Experimental studies have shown that activated
eosinophils could play a critical role in the pathogenesis
of liver diseases through the release of highly cytotoxic
granule proteins such as MBP, ECP, TNFα followed by
cell damage. The first experimental model to prove in vivo
eosinophil-induced hepatotoxicity was established by Tsuda
et al. in 2001 [190] by using IL-5 transgenic mice with
a consequent blood hypereosinophilia. These mice after
injection of LPS developed an extensive hepatic lobular
necrosis, associated with a transmigration of eosinophils
through vascular endothelium and degranulation of their
cytotoxic granules in inflamed areas. These eosinophilic
injuries were transient but liver specific. A recent study by
Takahashi et al. [191] has also demonstrated an increased
expression of galectin-9 and eosinophilic chemoattractant in
the liver biopsy of patients with drug-induced liver injuries.
Tarantino et al. [192] have reported an association between
liver fibrosis and eosinophilia infiltrate (EI), which could
be explained by the eosinophils’ ability to release TNF-α
and other cytokines capable of increasing an inflammatory
cascade and therefore stimulating the fibrogenic stellate
cells.
3.7. Dendritic Cells (DCs)
3.7.1. Phenotype and Function. Dendritic cells (DCs), first
discovered [193] by Steinman, are professional antigen-
presenting cells which control immunity and tolerance. They
initiate and regulate immune responses depending on signals
received from the invading microbes and their cellular envi-
ronment. They are a heterogeneous population which can be
divided into two major population; myeloid CD11c+ DCs
(mDCs) expressing DC-SIGN and plasmacytoid CD123+
DCs (pDCs) which are also known as IFN producing cells
[194, 195].
Myeloid DCs are HLA-DR+CD11c+ and express TLR
2, 3, 4, 5, 8. Myeloid DCs exist in three compartments;
peripheral tissues, secondary lymphoid organs and in cir-
culating blood. Peripheral tissue resident DCs consist of
Langerhans cells (epidermis, gut) and dermal interstitial DCs
[196]. Lymphoid organ resident DCs play a critical role
in both induction of immunity to invading pathogens and
maintenance of tolerance. They capture antigens and upon
stimulation via pattern recognition receptors, they induce
the proliferation of antigen-specific T cells. They are able to
present antigens to CD4+ and CD8+ T cells as well as B cells.
Plasmacytoid DCs are HLA-DR+CD123+, express TLR
7, 9, 10 and are present in blood, secondary lymphoid
organs and peripheral tissues (skin and lungs) [197]. Their
main function is to secrete IFN-α in response to viral
infections and to prime T cells against viral antigens [198].
Plasmacytoid DCs are also described as tolerogenic DCs
because they could induce regulatory T cells [199].
3.7.2. Dendritic Cells in Innate Immunity. Both myeloid
and plasmacytoid subsets are capable of initiating innate
immune responses that lead to elimination of invading
microbes. DCs express several receptors for recognising
viruses including pattern recognition receptors (PRRs) such
as the toll-like receptors (TLRs) and C-type lectins [200].
pDCs secrete large amount of type I IFN in response to viral
encounter [201]. Activated mDCs produce cytokines such as
interleukin-12, IL-15, and IL-18. IL-12 is crucial for mDCs to
induce T helper 1 (Th1) cell responses, which subsequently
promote the potent cytotoxic T lymphocyte (CTL) responses
that are necessary for clearing microbe-infected cells [202].
DCs detect microbes in peripheral tissue sites and,
following activation and microbe uptake, migrate to
draining lymph nodes, where they promote NK cell
activation. DCs also activate NKT cells to secrete IFN-γ
and IL-4 [203]. DCs trigger diﬀerent types of adaptive
T-cells immune responses based on antigen and cytokine
environment; they can promote IL-10 secreting regulatory
T-cell development [204]; induce Th1 response [205]
through upregulation of IL-12 secretion and Th2 responses
[206] via secreting Th2 cytokines.
3.7.3. Dendritic Cells in Hepatic Inflammation. Both plasma-
cytoid and myeloid DCs reside in the human liver. Hepatic
12 Mediators of Inflammation
DCs play important roles in the induction and regulation
of immune responses (Figures 3 and 4). Human liver is
constantly exposed to gut pathogens thus liver resident DCs
remain in an immature state expressing low levels of MHC
and costimulatory molecules CD40, CD80, and CD86. Intra-
hepatic DCs tend to act as tolerogenic cells preferentially
expressing IL-10 [207]. The constant exposure to bacterial
LPS via portal blood down-regulates the expression of TLR4
on liver DCs thus limiting their response to danger signals
and resulting in reduced or altered activation of the hepatic
adaptive immune responses. DCs also have the capacity to
expand functional CD4+CD25+ regulatory T cells [208, 209]
and recent study has suggested that CCR9+ plasmacytoid
DCs (pDCs) are capable of inducing regulatory T cells
and inhibiting antigen-specific immune responses both in
vitro and in vivo [210]. The role of DCs has been widely
described not only in viral and autoimmune diseases but
also in hepatocellular carcinoma and liver transplantation
[211, 212].
3.8. Natural Killer (NK) Cells
3.8.1. Phenotype and Function. NK cells, first described as
“pit cells” [213] are a crucial component of innate immune
system. They are abundant in the liver where they provide
a first line of defence against viral infections and tumour
immunity [214, 215]. Hepatic NK cells in mice consist of
5–10% of lymphocyte population and they are defined by
NK1.1+ (only for CD57BL/6 mice) CD3− or DX5+ CD3−. In
the human liver, NK cells consist approximately 20-30% of
liver resident lymphocytes [216] and they are CD56+CD3−.
Human NK cells can be divided into two major popu-
lations; CD56dim CD16bright CD3− and CD56high CD16dim
CD3−. The former comprise approximately 90% of periph-
eral circulating NK cell population. They constitutively
produce high numbers of cytolytic granules and are capable
of spontaneously lysing target cells in the absence of prior
sensitization. The latter consist the remaining 10% of circu-
lating NK cells that are poorly cytotoxic and express high
levels of C-type lectins and natural cytotoxicity receptors
(NCRs) and low levels of killer cell immunoglobulin-like
receptors (KIRs) [217]. These two NK cell subsets represent
diﬀerent stages of NK cell maturation, with the CD56dim NK
cells being the functionally and phenotypically mature cells
[218]. A third population of NK cells consisting of CD56−
cells has been demonstrated during chronic viral infections
[219]. They express a similar receptor profile to CD56low NK
cells but are poorly cytotoxic and do not secrete cytokines
[220–222].
3.8.2. NK Cell Recruitment in Liver. NK cells arrive very early
to the site of inflammation and generally reside in the hepatic
sinusoids. They express chemokine receptors CCR2 (which
responds to chemokine CCL2), CCR5 (ligands are CCL5,
CCL7, CCL8), CXCR3 (CXCL9-11), CX3CR1 (CX3CL1) and
S1PR (SIP) thus responding to a variety of chemokines.
Both CD56dim and CD56bright NK cell subsets migrate
to inflamed sites with more CD56dim being recruited to
inflamed liver. Previous studies have suggested that Kupﬀer
cell derived CCL2/MCP-1 recruits CCR2 expressing NK
cells to the liver [223, 224]. During hepatic inflammation,
activated liver sinusoidal endothelial cells express CXCL9-
11 chemokines (CXCR3 ligands) [225] which subsequently
recruit CXCR3 expressing NK cells to the liver. They also
secrete chemokines CCL3/ MIP-1α and CCL4/MIP-1β which
lead to subsequent T cells recruitment to the liver [226]. IFN-
γ secreted from NK cells favours development of Th1 cells
and upregulates CXCL9-11 chemokines (CXCR3 ligands)
on human hepatic sinusoidal endothelium thus will recruit
various inflammatory cells expressing CXCR3 chemokine
receptors.
3.8.3. NK Cells in Hepatic Inflammation. NK cells play a
significant role in antiviral and antitumour activity, liver
fibrosis, liver repair and may also be involved in hepatic
tolerance. NK cells main function in antiviral and antitumor
immunity depends on their proinflammatory cytokine IFN-
γ or their direct killing of infected or transformed target
cells such as virus-infected hepatocytes or hepatocellular
carcinoma. They have both inhibitory and stimulatory
receptors which act on their corresponding ligands on
target cells [227]. NK cells inhibitory receptors include killer
cell immunoglobulin-like receptors (KIRs) and CD94/NKG2
which recognize MHC class I molecules on target cells and
inactivate the function of NK cells. The activating receptors
include NKG2D, NCRs, and CD266 [220]. Thus, following
acute viral infection, chemokines from hepatic resident cells
recruit NK cells to inflamed liver and keep them in an
activated state to control the infection. However, in chronic
hepatitis C, studies have shown that NKG2 expression is
increased on NK cells which may contribute to persistence
of viral infection [221].
NK cells have also been suggested to be involved in
preventing hepatic fibrosis, via killing-activated stellate cells
which are key player in fibrosis due to its matrix deposition.
Depletion of NK cells in experimental murine models
enhances liver fibrosis [222].
NK cells may also be involved in hepatic tolerance. It
has been reported that LPS-stimulated Kupﬀer cells secrete
higher levels of the immunosuppressive cytokine IL-10,
which in turn leads to inactivation of NK cell function [222].
NK cells may also indirectly maintain hepatic tolerance via
dendritic cells which can induce tolerogenic regulatory T
cells in the presence of NK cells [228].
3.9. NKT Cells. NKT cells are part of the innate immune
system. They express both T-cell receptor and natural killer
cell surface markers. They are a heterogeneous group which
recognises lipid antigen presented by CD1d [229]. They
are classified based on MHC class I like molecule, CD1d
restriction as invariant NKT and noninvariant NKT cells.
CD1d-dependent NKT cells are again classified into Type I
and Type II NKT cells. Human NKT cells express TCR αβ
or TCR γδ and a variety of NK cell receptors, which include
CD161, CD69 and CD56 [230, 231].
Human intrahepatic NKT cells are defined as CD3+
CD56+ and consist of 10–15% of lymphocyte population but
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Figure 4: Linking innate and adaptive immune system. Dendritic cells from innate immune system present their antigen to naive T cells
at local draining lymph nodes. T-cell receptor (TCR) ligation to MHC class II associated peptides processed from pathogens (signal 1) and
binding of costimulatory molecule CD28 on lymphocyte to CD80 and CD86 expressed by dendritic cells (signal 2) leads to T-cell lineages
diﬀerentiation. Signal 3 is the polarizing cytokines signals from the innate immune cells. Depending on type of antigen which is presented
and nature of cytokines in the microenvironment, innate DC cells direct the development of Th1, Th2, Th17 lymphocytes lineages which
plays crucial role in adaptive immune system.
of that <1% is CD1d restricted invariant NKT. Intrahepatic
NKT cells play an important role in defence towards hepatic
infection or inflammation. Host antigen presenting cells
present microbial glycolipid antigens to CD1d and NKT cells
release Th1 (IFN-γ, TNF-α), Th2 (IL-4, IL-5, IL-10) or Th17
(IL-17, IL-22) cytokines which in turn activate other innate
immune cells and adaptive T cells [232].
3.9.1. NKT Cells and Hepatic Inflammation. NKT cells are
enriched in liver and play a diverse role in acute liver injury,
liver fibrosis and tolerance. It is due to diﬀerent types of
NKT cells and a variety of cytokines which they produce
upon stimulation. In the acute injury setting, injection of
α-GalCer, a specific ligand for invariant NKT will lead
to acute hepatitis [233]. NKT cells also play a role in
progressive fibrosis in nonalcoholic fatty liver disease both
in human and murine models via activation of Hedgehog
pathway [234]. NKT cells are implicated in hepatic tolerance.
One elegant study suggested that IFN-γ secreted from NK
cells upregulates CXCR3 ligands on hepatic sinusoid and
subsequently recruits CXCR3 expressing regulatory T cells to
control hepatic inflammation [235].
3.10. Innate Immune Cells Crosstalk Adaptive System in Hep-
atic Inflammation. Innate immune system provides signals
to stimulate the adaptive immune system by proliferation
and diﬀerentiation of antigen-specific T and B lymphocytes.
Antigen peptide acts as a signal 1 which presents the antigen
to [236] naive T cells via MHC-class II. Costimulatory
molecules such as CD28, CD80, and CD86 are present
on antigen presenting cells such as DCs to stimulate T
lymphocytes thus acting as signal 2 to link the innate and
adaptive immune response. Innate immune cells such as den-
dritic cells and macrophages produce polarizing cytokines in
response to microbes that also promote the diﬀerentiation
and growth of specific lymphocyte lineages. IL-12 stimulates
naive T lymphocytes to develop into Th1 eﬀector cells, IL-
4 and IL-13 stimulate them into Th2 phenotype and IL-
1, IL-6 and TGF-β into Th17 phenotype. Thus, polarizing
cytokines in the microenvironment will shape the naive T
cells into diﬀerent T eﬀectors lineages to counteract with
diﬀerent types of microbes (Figure 4).
3.11. Diagnostic and Therapeutic Clinical Application of
Innate Immune Systems. Innate immune proteins and cells
have been harnessed for many diagnostic and therapeutic
applications in human diseases. Acute phase protein CRP,
a mediator of inflammation and agent of innate immunity
is now used as a key diagnostic marker of cardiovascular
risk. Individuals with CRP levels <2mg/L have significantly
lower rate of coronary event. Thus, CRP levels are useful
in evaluating the risk of myocardial infarction [237, 238].
Complement component levels are normally measured to
assess the immune-mediated disorders and anaphylactic dis-
order such as hereditary angioedema. Tocilizumab, an anti-
IL-6 therapy has been used in rheumatoid arthritis, cancer
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therapy, and cancer-related anorexia [239]. Cell therapy uti-
lizing innate immune cells such as NK cells and DC is always
an attractive option for clinical immunologists. Human NK
cells immunotherapy is currently a promising tool as an
adjuvant therapy in acute myeloid leukemia patients along
with standard therapy [240, 241]. Furthermore, adminis-
tration of myeloid DCs that have been pretreated with
inactivatedHIV enhances immune control of HIV in patients
[242] and myeloid DCs pulsed with tumour antigen lysate
(APF) induce tumour specific immune responses along with
transarterial chemoembolization (TACE) in hepatocellular
carcinoma patients [243].
Many GMP grade clinical trials are now underway for
development of DC-based vaccine strategies in viral (HIV)
and carcinoma (such as hepatocellular carcinoma) to elicit
strong cytotoxic immune responses to overcome the immune
regulation. However, vaccine strategies and cell therapies
that aim to promote DC and NK cell responses during
viral infection and antitumour therapy would have to be
carefully monitored to prevent any deleterious consequences
of immune activation. Gradual understanding of how DCs
and NK cells are involved during viral infection at molecular
level may provide new targets for vaccine design or even
therapeutic modulation of disease with autologous cell
therapy in future.
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